Thyroxyl (T3) 25 mcg

Thyroxyl (T3) 25 mcg contains liothyronine sodium, which is FDA-approved as replacement therapy in primary, secondary, and tertiary hypothyroidism. It is also indicated as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism. The FDA label explicitly states it should not be used for obesity or weight loss.

In medically supervised therapy, liothyronine sodium is administered orally once daily. The recommended starting dosage is 25 mcg once daily, with increases of 25 mcg every 1 to 2 weeks as needed. Non-medical use often involves split dosing, though such use falls outside approved indications.

Liothyronine sodium does not suppress the hypothalamic-pituitary-gonadal axis, so standard anabolic steroid PCT is not applicable. The thyroid axis typically recovers on its own after cessation, though tapering is commonly referenced in non-medical contexts to avoid rebound hypothyroid symptoms. If T3 is used alongside suppressive anabolic compounds, standard PCT protocols should be followed for those compounds.

T3 is the biologically active thyroid hormone that helps the body use energy, stay warm, and keep the brain, heart, muscles, and other organs working properly. It exerts its effects through control of DNA transcription and protein synthesis, diffusing into the cell nucleus and binding to thyroid receptor proteins. Approximately 80% of T3 is derived from peripheral conversion of T4, with the remainder secreted directly by the thyroid.

Liothyronine sodium has a rapid onset of action, with effects occurring within a few hours and maximum pharmacologic response within 2 to 3 days. The biological half-life is approximately 2.5 days. This rapid onset distinguishes it from levothyroxine (T4), which has a slower onset and longer half-life.

There is no single thyroid medication that is universally best. The American Thyroid Association notes that recent studies have generally found no clinical advantage in adding T3 to the usual T4 replacement regimen. T3 has a more rapid onset and shorter half-life than T4, which can be advantageous or disadvantageous depending on the clinical situation. The appropriate formulation depends on individual medical circumstances.

T4 (thyroxine) is the main hormone secreted by the thyroid gland and is converted to T3 in peripheral tissues. T3 is the biologically active form that exerts most of the effects of thyroid hormones. T3 has a more rapid onset and shorter half-life (approximately 2.5 days) compared to T4, which has a longer half-life and slower onset.

A single 25 mcg tablet represents the standard recommended starting dosage for adult hypothyroidism. The usual maintenance dose is 25 mcg to 75 mcg once daily. In non-medical contexts, doses above the normal physiologic range are associated with signs and symptoms of hyperthyroidism, including arrhythmia and increased bowel motility.

Thyroxyl (T3) 25 mcg is labeled at 25 mcg of liothyronine sodium per tablet. It is supplied in packs of 100 tablets, giving 2,500 mcg of total labeled liothyronine sodium content per pack.

The FDA label explicitly states that liothyronine sodium should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction, and larger doses may produce serious or even life-threatening manifestations of toxicity. Weight loss should be pursued through appropriate diet and exercise under medical guidance.

Low T3 levels can indicate hypothyroidism, though T3 testing is rarely helpful in the hypothyroid patient since it is the last test to become abnormal. Patients can be severely hypothyroid with a high TSH and low free T4 but have a normal T3. Low T3 should be evaluated by a qualified healthcare professional in the context of other thyroid function tests.

Laboratory testing information for Thyroxyl (T3) 25 mcg is not currently available in this product listing. Kalpa Pharmaceuticals products are manufactured under pharmaceutical-grade conditions, but independent lab reports are not published for this specific product at this time.